Christopher M. Starr Sells 16,800 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) Director Christopher M. Starr sold 16,800 shares of Monopar Therapeutics stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the transaction, the director directly owned 5,173 shares in the company, valued at $206,920. This represents a 76.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Monopar Therapeutics Stock Up 3.3%

Monopar Therapeutics stock traded up $1.31 during midday trading on Wednesday, reaching $41.07. The stock had a trading volume of 26,967 shares, compared to its average volume of 362,258. Monopar Therapeutics Inc. has a 12 month low of $1.72 and a 12 month high of $54.30. The firm's 50-day moving average price is $35.63 and its 200 day moving average price is $35.88. The firm has a market capitalization of $251.35 million, a PE ratio of -11.80 and a beta of 1.01.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.27. Equities research analysts expect that Monopar Therapeutics Inc. will post -1.65 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on MNPR shares. Piper Sandler reiterated an "overweight" rating and set a $76.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. Chardan Capital started coverage on Monopar Therapeutics in a research note on Monday, June 23rd. They set a "buy" rating and a $60.00 target price on the stock. Wall Street Zen upgraded Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. Finally, Cantor Fitzgerald started coverage on Monopar Therapeutics in a research note on Monday, July 7th. They set an "overweight" rating and a $74.00 target price on the stock. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $60.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. AlphaQuest LLC purchased a new position in Monopar Therapeutics during the 1st quarter valued at about $44,000. JPMorgan Chase & Co. purchased a new position in Monopar Therapeutics during the 4th quarter valued at about $45,000. Gerber LLC purchased a new position in Monopar Therapeutics during the 1st quarter valued at about $204,000. OMERS ADMINISTRATION Corp purchased a new position in Monopar Therapeutics during the 1st quarter valued at about $328,000. Finally, Jane Street Group LLC purchased a new position in Monopar Therapeutics during the 1st quarter valued at about $377,000. Hedge funds and other institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.